Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just fine, thank you, despite a long evening trek to visit the home office. Thanks to a cup or two of stimulation, we are motoring along, as usual. And we invite you to do the same. After all, the neurons can use as much as you can offer, yes? So on that note, time to get cracking. Here are some tidbits to get you started. We hope your journey today is successful and you conquer the world. And please do keep us in mind if something saucy pops up. …

Unity Biotechnology (UBX), a biotech focused on developing drugs that address what it says is a fundamental mechanism of aging, released the first human data on its first experimental drug, a treatment for osteoarthritis, STAT explains. The data represent the first test in humans of some tantalizing basic science showing that killing old, or senescent, cells that collect in the body may reduce some symptoms of aging. The results are more promising than the expectations set by Unity and Wall Street analysts, many of whom did not expect any benefit at all on patient symptoms.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Given that communications theory holds that the most efficient group size is 5, why would a group of 24,500 mean this? From above “the lawyers maintain the idea offers a more practical approach to negotiations.”
    If “practical” means a huge increase in billable hour$ across the country, that I can grasp. But the suggestion smacks of the “swallowing an elephant” all at once paradigm – but that, of course, is just my “observation.” (And who am I?)

Comments are closed.